Home›Psychiatry› 11 risk factors identified for predicting relapse in patients with schizophrenia
11 risk factors identified for predicting relapse in patients with schizophreniaNew risk factors identified to predict schizophrenia relapse
Psychiatry researchPublished July 1, 2026Study authors: Tang Wenlong, Guan Chunlan, Ling Zhangbin, Zhang Xinmiao, Cui HuixiaPubMed ↗DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that the identified model allows for early identification of high-risk patients to facilitate targeted interventions.
This meta-analysis investigated the identification and quantification of risk factors influencing relapse in patients with schizophrenia. The study analyzed a large aggregate population of 159,973 participants to identify key predictors of clinical deterioration. To ensure the robustness of the findings, a validation set consisting of 452 records was utilized to test the predictive accuracy of the resulting model.
The primary objective was to establish a reliable prediction model for relapse risk. The analysis identified 11 specific relapse risk factors among the total cohort. From the initial pool of 159,973 participants, 5,924 relapses were documented. These factors were then integrated into a logistic regression model to determine the probability of relapse.
The resulting prediction model was defined by the following coefficients: Logit(P) = α + 1.477X + 1.495X + 0.604X + 0.668X + 1.637X + 1.351X + 1.141X + 1.413X + 0.888X + 0.582X + 1.281X. This model was evaluated using secondary outcomes including the Hosmer-Lemeshow test, calibration curves, and decision analysis to determine its predictive reliability.
Regarding safety and tolerability, no specific adverse events, serious adverse events, or discontinuation rates were reported in the data provided. The study focused on the identification of risk factors rather than the evaluation of a pharmacological intervention, thus clinical tolerability metrics were not applicable to the primary findings.
While this meta-analysis provides a large-scale overview of risk factors, it is important to note that the results are based on observational and case-control data. Therefore, these associations do not imply causality. The study's predictive ability is characterized as moderate. Furthermore, the 'good diagnostic performance' noted in some contexts is specifically tied to the external validation set of 452 records.
The clinical implications of this research are significant for patient management. The identified model allows for the early identification of high-risk patients within a clinical population. By identifying these individuals earlier, clinicians can implement targeted interventions designed to mitigate relapse and improve long-term outcomes for patients with schizophrenia.
Several questions remain regarding the specific nature of the 11 risk factors and how they may vary across different demographics or subtypes of schizophrenia. Additionally, while the model shows promise in a large meta-analysis context, its real-world application depends on the integration of these specific variables into routine clinical screening tools.
How this fits prior evidence
How this fits prior evidence
This meta-analysis addresses a gap in identifying objective risk factors for relapse in schizophrenia. While previous research has identified neurophysiological signatures using qEEG to distinguish chronic schizophrenia from early psychosis and noted elevated GFAP levels as a biomarker, this study focuses on the identification of 11 specific risk factors to predict clinical relapse. It provides a different layer of evidence by focusing on predictive modeling rather than biochemical or neuroimaging markers.
Managing schizophrenia is a lifelong journey for many people. One of the biggest challenges for both patients and their families is the risk of relapse, which can disrupt stability and lead to more difficult periods of illness. Because early intervention is so important, finding ways to identify who might be at higher risk for a relapse is a major goal for medical researchers. This research aims to provide tools that could help doctors stay ahead of these changes.
the researchers conducted a large meta-analysis involving data from nearly 160,000 participants. They looked specifically at the factors that influence whether a person with schizophrenia experiences a relapse. To ensure their findings were reliable, they also tested their results against a separate group of 452 people to see if the patterns held true in different settings. This large scale of data helps create a more stable picture of risk than a small study could provide.
The analysis identified eleven specific factors that contribute to the risk of relapse. By looking at these variables, researchers developed a mathematical model designed to predict who might be at higher risk. The results showed that this model had moderate predictive ability. This means it can help identify certain patterns in a patient's situation or history that suggest they may need more intensive support or closer monitoring from their medical team.
While the study provides a useful tool for identifying risks, there are important things to keep in mind. Because this was a meta-analysis of observational data, it shows links between factors and relapse rather than proving that one specific factor causes a relapse. Additionally, while the model showed good performance in testing, its real world application depends on how accurately these eleven factors can be measured in daily clinical practice.
For patients and families right now, this research does not change immediate treatment plans or medications. However, it offers hope for the future of personalized care. If these risk factors can be easily tracked by doctors, it could lead to more proactive care. Instead of waiting for a relapse to happen, healthcare teams might be able to step in earlier with targeted support to keep patients stable and healthy.
What this means for you:
A large study identified 11 risk factors that may help doctors predict and prevent relapses in schizophrenia.
BACKGROUND: The high relapse rate in patients with schizophrenia imposes a significant burden on both families and society, hindering patients' recovery. Predictive modeling of relapse risk factors aids in early identification of high-risk patients for timely intervention.
METHODS: A comprehensive search of multiple databases was conducted to collect both domestic and international publications on factors influencing relapse in patients with schizophrenia, up to July 1, 2024. After literature screening, data extraction, and quality assessment by two researchers, meta-analysis was performed using RevMan 5.4 software to calculate combined odds ratios (OR) and 95% confidence intervals (CIs). A risk prediction model was constructed based on the natural logarithmic transformation of the composite hazard values. Inpatient medical records of patients with schizophrenia from Wuhu Fourth People's Hospital, collected between January 2022 and July 2024, were screened for analysis. The model's effectiveness in predicting relapse risk was validated through multiple curves and decision analysis.
RESULTS: A total of 35 papers (27 cohort studies and 8 case-control studies), involving 159,973 participants and 5924 relapses, were included in the analysis. The meta-analysis identified 11 relapse risk factors. The corresponding logistic regression risk prediction model is: Logit(P) = α + 1.477X + 1.495X + 0.604X + 0.668X + 1.637X + 1.351X + 1.141X + 1.413X + 0.888X + 0.582X + 1.281X. The model was validated using an external dataset of 452 medical records, demonstrating good diagnostic performance. The Hosmer-Lemeshow test, calibration curves, and decision analysis further confirmed the model's accuracy and high clinical applicability.
CONCLUSION: An evidence-based predictive model for relapse risk in patients with schizophrenia was developed, demonstrating moderate predictive ability. This model allows for early identification of high-risk patients and facilitates targeted interventions to improve outcomes.
